Targeting BRAF Class II and III Mutations in NSCLC with the pan-RAF inhibitor Exarafenib Reveals ARAF-KSR1-Mediated Resistance and Rational Combination Strategies.
使用泛 RAF 抑制剂艾沙非尼靶向 NSCLC 中的 BRAF II 类和 III 类突变，揭示了 ARAF-KSR1 介导的耐药性和合理的联合治疗策略。
期刊:
影响因子:
doi:10.21203/rs.3.rs-5135027/v1
Manabe Tadashi, Bergo Hannah C, Li Qingtian, Wang Tim Sen, Severson Paul, Miller Nichol, Lee Catherine, Donderici Elifnur Yay, Zhang Nicole, Wu Wei, Chou Yu-Ting, Kerr Daniel L, Allegakoen Paul, Grandinetti Kathryn B, Soroceanu Liliana, Pelham Robert J, Martin Eric S, Murphy Eric A, Khanna Vishesh, Neal Joel W, Chen Christopher T, Kato Shumei, Williams Richard, Bivona Trever G
